The Cure Circle podcast

Why CMC and Manufacturing Decide CGT Success

0:00
1:06:27
Rewind 15 seconds
Fast Forward 15 seconds

In this episode of The Cure Circle, host Dr. Smita Karpate, MD is joined by Emily Moran, Founder of 3LB Consulting, a global expert at the intersection of cell and gene therapy manufacturing, CMC strategy, and regulatory execution.

While cell and gene therapies promise cures once thought impossible, most programs do not fail because of weak science — they fail because execution breaks down. Emily’s work focuses on closing that gap: translating beautiful biology into manufacturable, compliant, and patient-ready therapies.

Drawing from nearly two decades in life sciences, vaccines, and advanced therapies — and a deeply personal experience with her own children in a Phase I clinical trial — Emily brings a rare dual lens to this conversation: the precision of an operator and the urgency of a parent.

This episode goes beyond discovery and dives into the realities that determine whether a therapy ever reaches patients: IND readiness, CDMO selection, CMC strategy, GMP design, regulatory inspections, and investor confidence.


In this episode, Dr. Smita Karpate, MD and Emily Moran discuss:

  • Why cell and gene therapy is ultimately an execution challenge, not just a scientific one

  • How academic science must evolve to meet IND, CMC, and GMP expectations

  • When and how scientists and clinicians should engage strategic partners and CDMOs

  • What truly matters in CDMO selection — and how the wrong choice can derail years of work

  • Why CMC strategy is the backbone of both regulatory success and investor confidence

  • The concept of right-size process design in an uncertain, patient-driven market

  • How regulators evaluate cell and gene therapy differently from traditional pharma

  • Why manufacturing discipline, transparency, and focus determine patient safety

  • How close we really are to patients — beyond clinical trials and hype

  • What founders, scientists, and clinicians should not delay if they want to succeed in CGT

This conversation is a grounded, unsentimental look at what it actually takes to deliver cures — from lab benches to clean rooms to patients’ lives.

Episode by episode, The Cure Circle builds the missing bridge between innovation and impact.

This discussion is essential listening for anyone serious about bringing cell and gene therapies to the world.

Subscribe, share, and join us as we explore the people, the systems, and the responsibility behind cure.

More episodes from "The Cure Circle"